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Received July 14, 2012; accepted December 13, 2012AbstractBackground: Erectile dysfunction (ED) has been a prevalent disease worldwide. The mainstay of treatment for ED focused on oral medications
such as phosphodiesterase-5 (PDE-5) inhibitors or other medical aids with variable acceptance. Trazodone is a second-generation antidepressant
approved by the U.S. Food and Drug Administration in 1981. Some evidence has suggested that trazodone may be helpful in improving ED,
especially for problems dealing with male arousal. Although controversial, trazodone can sometimes be used for ED as an off-label medication
for urological patients. By using a nationwide health insurance database, we attempted to estimate and thereafter analyze the existence and
extent of off-label use of trazodone for ED in Taiwan.
Methods: The 1/500 randomly sampled outpatient visits dataset and the 1/1 million randomly selected dataset issued in 2000 in the National
Health Insurance Research Database were used to estimate the total number of visits and the urological visits involving trazodone pre-
scriptions. The refill rate, patient age at first prescription, and the diagnoses assigned to the prescription visits were also gathered and
analyzed.
Results: The prescription visits in urological clinics consisted exclusively of male patients (99.0  1.3%, p < 0.001). The use of trazodone was
more prevalent and regular among the elderly ( p < 0.001), which happens to parallel the trend of incidence rates of ED. Starting in 1998, the
prescription rate for trazodone increased rapidly, but then slowed, equalized, and topped out in 2003. One of the reasons for this marked change
in prescriptions rates in Taiwan may be the increased awareness of ED as a treatable disease under the promotion and marketing of three PDE-5
inhibitors. ED-related diagnoses assigned to the prescription visits accounted for 55% of total visits, whereas anxiety/depression-associated
diagnoses were the bases of less than 13%, and those attributed to insomnia accounted for 2.3% of visits.
Conclusion: Despite the fact that trazodone was not officially approved for patients with urological conditions, this medication has been used as
an ED treatment in Taiwan at least since 1997; the prescriptions of trazodone were more prevalent among the elderly, and this trend increased,
then evened out, and eventually reached its maximum point in 2003, correlating with the introduction of PDE-5 inhibitors.
Copyright  2013 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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Erectile dysfunction (ED) is a worldwide problem. In
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http://dx.doi.org/10.1016/j.jcma.2013.05.002older than 40 years.1 The treatment of EDwas challenging prior
to the development of phosphodiesterase-5 (PDE-5) inhibitors.
Many drugs have reportedly been used to treat ED, including
trazodone.2 The use of trazodone to treat ED, especially for
arousal problems, has not been approved in Taiwan; it is indi-
cated as an antidepressant in Taiwan and as a hypnotic in several
other countries.3 Although controversial, it is believed that
trazodone has been used for some time as an off-label medica-
tion for ED or arousal problems in urological patients.hinese Medical Association. All rights reserved.
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scription patterns in urological clinics in Taiwan, using in-
formation derived from the National Health Insurance
Research Database (NHIRD), a prospectively collected data-
base open to qualified researchers. We believe that our
research represents the first nationwide, cross section study of
trazodone use within the urological specialty.
2. Methods
The National Health Insurance Program single payer sys-
tem was launched in Taiwan on March 1, 1995. Since its
inception more than 15 years ago, more than 98% of the
island’s population has received nearly all forms of health care
services under the program. For research purposes, NHIRD
data are derived from this system by the Bureau of National
Health Insurance in Taiwan and maintained by the National
Health Research Institutes. Each year, the Bureau of National
Health Insurance collects information, including registration
files and original claims for reimbursement, into larger data
files. Data that could be used for identification of patients and
care providers is scrambled prior to database reconstruction
and prior to being released to researchers. We also followed
the related research regulations of the National Health
Research Institutes and those of our hospital in the present
study. The Details of Ambulatory Care Orders Dataset
(DACOD) and the Longitudinal Health Insurance Database
2000 (LHID 2000) of the NHIRD were used for our data
analysis. The DACOD database includes all the ambulatory
orders, including laboratory examinations and medications.
The dataset was at first sampled randomly on a scale of 1:500
to reduce the data size; trazodone use in all clinics and in
urological clinics was then identified, stratified by year from
1997 to 2008. The LHID 2000 is an official cohort dataset
containing all the original claim data of 200,000 individuals
randomly sampled from the year 2000 Registry for Benefi-
ciaries of the NHIRD. There were no statistically significant
differences between the LHID 2000 and all enrollees accord-
ing to the National Health Research Institute’s reports. Patients
with trazodone prescriptions each year, the patient age at first
prescription, and the diagnoses for urological visits with
trazodone were processed from the LHID 2000. These patients
were further subgrouped into adolescents (<20 years old),
young adults (20 years old but <40 years old), adults (40
years old but <60 years old), and the elderly (60 years old).
A frequent user of trazodone was defined as a user who ob-
tained at least three refills of trazodone from urological clinics.
According to our clinical experiences, ED patients are
customarily designated with the International Codes of
Disease-9, Clinical Modification (ICD-9 CM) 607.84 (impo-
tence of organic origin), 302.7 (psychosexual dysfunction),
and 302.9 (unspecified psychosexual disorder) in Taiwan.
These codes have been used in this study to represent patient
diagnosis. ICD-9 CM 296 (affective psychoses), 300 (neurotic
disorders), and 311 (depressive disorder, not elsewhere clas-
sified) were the codes defined as anxiety/depression-related
diagnoses. ICD-9 CM 307.40 (nonorganic sleep disorder,unspecified), 307.41 (transient insomnia), and 307.42 (persis-
tent insomnia) were used to represent insomnia in the present
study. ICD-9 CM 607.3 was the code for priapism.
The data were analyzed using the ManneWhitney test,
KruskaleWallis test, and Pearson’s Chi-square test, with
ActivePerl 5.12.1 software from ActiveState (Vancouver, BC,
Canada). A p value <0.05 was defined as statistically
significant.
3. Results
A total of 20,269 outpatient visits with prescriptions for
trazodone were identified from the 1/500 randomly sampled
DACOD from 1997 to 2008. In all clinics, women
(51.6  2.6%) received the medication significantly more
frequently than men (48.3  2.5%, p ¼ 0.009). By contrast,
male patients (99.0  1.3%) accounted for the large majority
of patients receiving trazodone in urological clinics under all
kinds of diagnoses ( p < 0.001), although the rate of usage
declined dramatically since 2004 (Fig. 1).
There were 514,069 male patients in LHID 2000, and 4676
patients had visited urological clinics for trazodone prescrip-
tion, for a total of 18,052 visits. Among these 4676 patients,
up to 55.1% were assigned with a code for ED-related con-
ditions. Of the total, 7.8% had both the diagnosis codes for
anxiety/depression and ED, and 4.5% were diagnosed with
anxiety/depression-related disorders. Only 2.3% of patients
were coded with insomnia (Fig. 2). There were 21 patients
diagnosed with priapism after the prescription of trazodone,
which had an estimated incidence of this potentially adverse
effect of 0.45%.
Among those receiving trazodone from urological clinics
without ICD-9 CM codes of ED or anxiety/depression (about
30.2% of all patients), the ratio of patients taking daily dosage
between 25 mg and 50 mg was 22.0%, 34.0%, or 32.3% if we
assumed that the prescription duration was 7 days, 14 days, or
28 days, respectively. That is, the trazodone use rate in uro-
logical clinics (at a lower dose for insomnia) was estimated to
be about 6.7e10.4%; however, when it came to patients taking
trazodone solely under the ED diagnosis (55.1% of all pa-
tients), the estimated ratio of patients taking low dose of
trazodone was 19.3%, 38.1%, or 37.0%, respectively.
The prescription and new prescription rates of trazodone
use in urology outpatients in Taiwan were also estimated from
the LHID 2000 (Fig. 3). The mean prescription rate from 1997
to 2008 is 0.117  0.033%, peaking in 2002 (0.155%). The
mean new prescription rate from 1998 to 2008 is
0.086  0.023%, which achieved its maximum in 2003
(0.114%). The most prevalent use of trazodone was noted
among the elderly, as well as the incidence rate, but both
started to decline after 2003. Adolescents had the lowest use
rate of all groups.
Frequent use accounted for 26.60% of all trazodone pre-
scriptions in urological clinics and 87.1% of frequent users
started taking trazodone after 40 years of age. Of all trazodone
prescriptions, 48.0% were coded with ED only and 9.4% were
diagnosed with depression only. Patients with ED and
Fig. 1. Yearly trazodone use in total and urological visits. In all clinics (upper), women (mean 51.6  2.6%) received the medication significantly more frequently
than men (mean 48.3  2.5%, p ¼ 0.009); in urological clinics (lower), male patients (mean 99.0  1.3%) accounted for the vast majority receiving trazodone
( p < 0.001). Numbers in each bar are the absolute prescription numbers by years.
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tween the rate of frequent use and the patients’ age was
demonstrated with Chi-square test ( p < 0.001), from 3.57% in
adolescents to 33.31% in the elderly (Fig. 4).
4. Discussion
ED, defined as the persistent inability to achieve or main-
tain an erection sufficient for satisfactory sexual performance,4
has been a prevalent problem worldwide. In Taiwan, a recent
questionnaire-based study estimated the prevalence rate of EDup to 27% among Taiwanese men more than 30 years of age,
and 29% among those older than 40 years.1 ED may deteri-
orate overall life satisfaction and health-related quality of life,
especially in the emotional, relational, and sexual domains.5,6
Moreover, the relationship between ED and depressed mood
may be bidirectional: the presence of either condition may
trigger or exacerbate the other; for example, ED could
contribute additional distress to patients with depression,
resulting in prolonged or worsened depressive illness, and
subsequent noncompliance with the treatment.7 There were
also interactions between the treatments for both conditions.
Fig. 2. Diagnoses for trazodone use in urological male patients. Up to 55.1%
were assigned with code with ED-related conditions; 7.8% had both the
diagnosis codes for anxiety/depression and ED, and 4.5% were diagnosed with
anxiety/depression-related disorders. Only 2.3% of patients were coded with
insomnia.
Fig. 3. Current and new trazodone prescription trends for male Taiwanese each
year, stratified by age. The mean prescription rate from 1997 to 2008 is
0.117  0.033%, peaking in 2002 (0.155%). The mean incidence rate is
0.086  0.023%, which achieved maximum in 2003 (0.114%). The most
prevalent use of trazodone was noted among the elderly, as well as the inci-
dence rate, but both started to decline since 2003. Adolescents had the lowest
use rate of all groups.
Fig. 4. Frequent versus infrequent refill of trazodone in urological male pa-
tients. A positive correlation between the rate of frequent use and the patients’
age was demonstrated with Chi-square test ( p < 0.001), from 3.57% in the
adolescents to 33.31% in the elderly.
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antidepressants, are highly associated with the side effect
of ED.8,9
Treatment options for patients with ED include psycho-
sexual therapy, penile prostheses, revascularization, vacuum
constriction devices, intracavernous injection, transurethral,
and oral drug therapy.10 Jarow et al11 have shown a patient
preference for less invasive treatment for ED (such as oral or
transurethral drug therapy) despite the higher satisfaction rate
with alternatives that involve surgical intervention.
Trazodone hydrochloride possesses antidepression effects
by acting as a serotonin antagonist reuptake inhibitor. It was
noted to cause enhanced libido and priapism.12e14 In one
animal study, this erectogenic effect may result from its pri-
mary metabolite, m-chlorophenylpiperazine, interacting with
the 5-HT1C receptor.15 Several studies then reported that
trazodone can be an option for selected patients with psy-
chogenic ED at higher doses.2,16e19 However, debate
continued regarding the prescription of trazodone for ED,20,21
and it has no indication for ED in Taiwan. Thus, trazodone for
ED treatment is an “off-label use.”
Off-label use means the use of a medication or device
deviating from what is mentioned in its U.S. Food and Drug
Administration product label. It is common, legal, and an
important source of innovation; however, it can be costly and
strong evidence of the efficacy and safety of the drug for its
off-label use may be lacking.22 The Food and Drug Admin-
istration generally prohibits off-label indications from being
promoted to physicians and consumers, but not prescriptions
by physicians. There are different, conflicting points of view in
the health care system when it comes to off-label usedthe
pharmaceutical industry seeks to enlarge product markets, and
payers such as the National Health Insurance doubt the need to
pay for unproven and costly products. The public had
demonstrated that it wants medications not only to be safe and
effective, but further wants access to the newest therapies. To
be autonomous and also meet the needs of individual patients
are the wishes of many physicians. Ineffectiveness of the off-
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quently, thorough and comprehensive communication should
be made by physicians to their patients, to most effectively
address the individual needs of patients and provide detailed
explanation of the off-label prescription for informed consent.
What was the true condition of trazodone use in the field of
urology under strict payment regulations? Depression-related
disorder, the only indication for trazodone in Taiwan, is
more prevalent in young adults, especially female patients.23
From this study, the gender distribution of trazodone pre-
scription in all clinics between 1997 and 2008 was comparable
with that of depression-related disorder. When urological
clinics were involved, trazodone was used exclusively by male
patients; moreover, frequent male users got their first trazo-
done prescriptions in urological clinics primarily after their
40s. These findings showed that trazodone was not used for
depression-related diagnoses. The gender and age distribution
of prescriptions in urological clinics in Taiwan was compatible
with the prevalence of ED in Taiwan.24 From the tentative
diagnoses assigned for prescriptions with trazodone by urol-
ogists, we could prove that trazodone use in the urological
field in Taiwan was mainly for ED during the period investi-
gated: more than 50% of male patients received their trazo-
done prescriptions for ED-related diagnoses; only 4.5% of
trazodone use originated from anxiety/depression-related di-
agnoses (Fig. 2). However, this trend was difficult to confirm
strictly from dosage differences because we could only obtain
information on the total amount not the exact daily dose of a
drug from LHID 2000. The ratio of patients taking trazodone
at a lower dose under the isolated diagnosis of ED was similar
or even higher than the ratio of patients without ED and
anxiety/depression diagnoses. It seems that, in high propor-
tion, urologists in Taiwan treat patients with ED with trazo-
done at a low dose.
The first phosphodiesterase type-5 (PDE-5) inhibitor [sil-
denafil (Viagra)] has been available in Taiwan since March
1999. The other two PDE-5 inhibitors currently available in
the country [vardenafil (Levitra) and tadalafil (Cialis)] have
been in the market since November 2003. Although these
drugs are excluded by National Health Insurance coverage,
they have had an extraordinary influence on the diagnosis and
treatment of ED. Kaye and Jick25 demonstrated a 2- to 3-fold
increase in the annual incidence of ED in the United Kingdom
during 1998e2000. A similar condition can be seen in Taiwan,
where the introduction of sildenafil prompted more men to be
aware that ED is a curable disease and to seek treatment. Jiann
et al26 reported that the yearly sales of sildenafil in Taiwan in
1999 reached 1,085,116 tablets, which increased 136% in
2002 (up to 2,566,512 tablets). With the launch of sildenafil in
1999, the new users of alprostadil injection almost doubled
from 1999 to 2002 in their institute,26 similar to the observed
trend of trazodone prescription in urological clinics in our
study. A retrospective study by Sullivan et al27 also disclosed a
rise in prescriptions issued for ED after the introduction of
sildenafil, which reached a plateau after 12e15 months. If
trazodone was used merely as an antidepressant in male
urology patients, there should not be a steep increase and aplateau in its prescription and new prescription from 1997 to
2003. After vardenafil and tadalafil started to be sold in
Taiwan, the prescription of trazodone in urological clinics
declined because of more treatment choices, as well as the
acceptance of PDE-5 inhibitors by the public. The correlation
between the introduction of sildenafil and the boost in trazo-
done prescriptions precisely demonstrated how trazodone was
used as a choice for ED treatment during the investigated
period.
Theoretically, trazodone should be more suitable for young
psychogenic impotent patients without major organic find-
ings.2 However, frequent users in the present study were
generally older than 40 years. It is possible that, for younger
patients, improvement in erectile function from taking several
doses of trazodone could break the vicious cycle of perfor-
mance anxiety. It is also possible that, for the elderly, car-
diovascular disease with concomitant use of nitrate
discouraged urologists from prescribing PDE-5 inhibitors, thus
rendering trazodone as the available treatment option for these
less physically fit patient population. Constitutionally there are
more old men in urological clinics, as well as higher rates of
insomnia among the elderly, both of which are possible
reasons.
There are several limitations to this study. First, we could
not demonstrate the interrelationship between prescribing
PDE-5 inhibitors and trazodone in the same cohort population,
because PDE-5 inhibitors are not covered by National Health
Insurance. Second, other confounding factors affecting trazo-
done prescriptions could not be totally excluded. Third, the
placebo effect of trazodone as a treatment choice for ED is
difficult to evaluate. Fourth, the change in government policy
and the spread of new research results about the effect of
trazodone for ED among urologists from 1997 to 2008 would
also affect the prescription of this medication. Lastly, the
NHIRD, a database derived from registration files and claim
data for reimbursement, lacked information about daily dosage
or patients’ response.
However, off-label use of trazodone as a treatment of ED in
urological clinics in Taiwan did exist. Although debate con-
tinues about the effectiveness of trazodone for the treatment of
ED, apparently some urologists in Taiwan view it as a treat-
ment choice for ED, under the risk of payment rejection;
moreover, some patients with ED in Taiwan visit urological
clinics, asking for trazodone for their ED more than one time.
This provides a hint that trazodone may be effective in certain
patients. Previous research concerning trazodone as a treat-
ment for ED was mainly based on Caucasian populations.
Whether there is racial difference in response to trazodone is
unknown, and who would benefit from off-label use of traz-
odone requires more investigation. However, this population-
based research applying administrative database can be a
stepping stone to further research on trazodone use in Asian
patients with ED, providing an additional choice for ED
treatment for those who could not tolerate or have contrain-
dications for PDE-5 inhibitors. Clinicians should continue to
monitor patients on trazodone for rare but significant adverse
effect of priapism, and further when new drug combinations
437W.-M. Cheng et al. / Journal of the Chinese Medical Association 76 (2013) 432e437involving trazodone are considered. Patients need to be
educated to increase their awareness of the side effects of
trazodone, and report any such effects early to best impact
long-term morbidity. Further clinical trials may be warranted
to investigate the safety and effectiveness of trazodone, as well
as the optimized dosage for ED.
In conclusion, from the NHIRD, we demonstrated a cor-
relation between the introduction of PDE-5 inhibitors and the
frequency of prescription of trazodone from 1997 to 2008.
Prescription use, although uncommon, was more prevalent
among the elderly, rather than among the younger patients. It
is likely that trazodone was used primarily for treatment of ED
rather than anxiety/depression or insomnia in the urological
field in Taiwan. However, the safety, cost-effectiveness, and
optimized dosage of trazodone as an oral alternative for pa-
tients with ED need further investigation.
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